Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00004179 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 475
Last updated 2021-02-15
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether chemotherapy is more effective with or without rituximab for relapsed non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying combination chemotherapy and rituximab to see how well they work compared to combination chemotherapy alone in treating patients with relapsed non-Hodgkin's lymphoma.
Conditions
Interventions
- BIOLOGICAL
- DRUG
-
CHOP regimen
- DRUG
- DRUG
-
doxorubicin hydrochloride
- DRUG
- DRUG
-
vincristine sulfate
Sponsors & Collaborators
-
Lymphoma Trials Office
collaborator OTHER -
Stichting Hemato-Oncologie voor Volwassenen Nederland
collaborator OTHER -
Australasian Leukaemia and Lymphoma Group
collaborator OTHER -
NCIC Clinical Trials Group
collaborator NETWORK -
Nordic Lymphoma Group
collaborator NETWORK -
European Organisation for Research and Treatment of Cancer - EORTC
lead NETWORK
Principal Investigators
-
M. H. J. Van Oers, MD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
-
Robert Marcus, MD · Cambridge University Hospitals NHS Foundation Trust
-
Max M. Wolf, MD · Peter MacCallum Cancer Centre, Australia
-
Richard J. Klasa, MD · British Columbia Cancer Agency
-
Eva K. Kimby, MD, PhD · Karolinska Institutet
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-05-31
- Primary Completion
- 2004-04-30
- Completion
- 2017-07-19
Countries
- Australia
- Belgium
- Canada
- Denmark
- Egypt
- France
- Hungary
- Italy
- Netherlands
- New Zealand
- Norway
- Poland
- Portugal
- Slovakia
- Slovenia
- South Africa
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00078949 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
NCT00881387 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00053105 ·Status: UNKNOWN ·Phase: PHASE1
-
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00007852 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00006029 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
NCT00002565 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
NCT00310128 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
NCT00654732 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT03710772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00513955 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964 ·Status: WITHDRAWN ·Phase: PHASE1
-
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
NCT00651755 ·Status: COMPLETED ·Phase: NA
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977 ·Status: COMPLETED ·Phase: PHASE3
-
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
NCT06018129 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003784 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
NCT00363090 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00012207 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00722137 ·Status: COMPLETED ·Phase: PHASE3
-
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
NCT00070187 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720 ·Status: RECRUITING ·Phase: PHASE2
-
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00080847 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00006250 ·Status: UNKNOWN ·Phase: PHASE3
-
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
NCT00644124 ·Status: COMPLETED ·Phase: PHASE1